These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3162904)

  • 21. The absorption and disposition of enoxacin in healthy subjects.
    Somogyi AA; Bochner F
    J Clin Pharmacol; 1988 Aug; 28(8):707-13. PubMed ID: 3216037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of food on enoxacin absorption.
    Somogyi AA; Bochner F; Keal JA; Rolan PE; Smith M
    Antimicrob Agents Chemother; 1987 Apr; 31(4):638-9. PubMed ID: 3475034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study.
    Davies BI; Maesen FP; Teengs JP
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():83-9. PubMed ID: 6594325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of the 4-quinolone enoxacin on plasma theophylline concentrations.
    Wijnands WJ; Vree TB; Van Herwaarden CL
    Pharm Weekbl Sci; 1986 Feb; 8(1):42-5. PubMed ID: 3457357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg.
    Danesi R; Lupetti A; Barbara C; Ghelardi E; Chella A; Malizia T; Senesi S; Angeletti CA; Del Tacca M; Campa M
    J Antimicrob Chemother; 2003 Apr; 51(4):939-45. PubMed ID: 12654753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone penetration of enoxacin in patients with and without osteomyelitis.
    Fong IW; Rittenhouse BR; Simbul M; Vandenbroucke AC
    Antimicrob Agents Chemother; 1988 Jun; 32(6):834-7. PubMed ID: 3166359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elimination of enoxacin in renal disease.
    Bury RW; Becker GJ; Kincaid-Smith PS; Moulds RF; Whitworth JA
    Clin Pharmacol Ther; 1987 Apr; 41(4):434-8. PubMed ID: 3470166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin.
    Rohwedder R; Bergan T; Caruso E; Thorsteinsson SB; Della Torre H; Scholl H
    Chemotherapy; 1991; 37(4):229-38. PubMed ID: 1790720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
    Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
    Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decrease of caffeine elimination in man during co-administration of 4-quinolones.
    Stille W; Harder S; Mieke S; Beer C; Shah PM; Frech K; Staib AH
    J Antimicrob Chemother; 1987 Nov; 20(5):729-34. PubMed ID: 3480885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral treatment of systemic Pseudomonas aeruginosa infection with enoxacin.
    Hubrechts JM; Vanhoof R; Servais J; Toen R; Sacré J; van Gysel JP
    Lancet; 1984 Apr; 1(8381):860. PubMed ID: 6143180
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections.
    Marchbanks CR; Mikolich DJ; Mayer KH; Zinner SH; Dudley MN
    Antimicrob Agents Chemother; 1990 Oct; 34(10):1966-72. PubMed ID: 2291662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Enoxacin concentration in seminal fluid, in prostate secretions and in prostatic adenoma tissue following oral administration or intravenous infusion].
    Naber KG; Sörgel F; Kees F; Schumacher H; Sigl G; Zürcher J; Berger S
    Infection; 1989; 17 Suppl 1():S30-6. PubMed ID: 2478481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enoxacin in acute exacerbations of chronic bronchitis: a comparison with amoxycillin.
    Prigogine T; Glupczynski Y; Carpiaux JP; Blogie M; Yourassowsky E; Schmerber JS
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():131-6. PubMed ID: 3129390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue penetration and clinical efficacy of enoxacin in respiratory tract infections.
    Wood MJ
    Clin Pharmacokinet; 1989; 16 Suppl 1():38-45. PubMed ID: 2653694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia.
    Simon N; Sampol E; Albanese J; Martin C; Arvis P; Urien S; Lacarelle B; Bruguerolle B
    Clin Pharmacol Ther; 2003 Oct; 74(4):353-63. PubMed ID: 14534522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enoxacin in the treatment of lower respiratory tract infections.
    Philip-Joet F; Nourrit J; Frances Y; Arnaud A
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():125-9. PubMed ID: 3258863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enoxacin-induced modification of the susceptibility of bacteria to phagocytic killing.
    Pruul H; Kriek G; McDonald PJ
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():19-27. PubMed ID: 3129391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quinolone penetration into canine vaginal and urethral secretions.
    Gasser TC; Graversen PH; Larsen EH; Dørflinger T
    Scand J Urol Nephrol Suppl; 1987; 104():101-5. PubMed ID: 3481457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Enoxacin concentration in human prostatic tissue].
    Yasumoto R; Kobayakawa H; Asakawa M
    Hinyokika Kiyo; 1986 Oct; 32(10):1471-3. PubMed ID: 2436463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.